Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus HUMATIN.
GENTAMICIN SULFATE vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic